Influence of food-derived advanced glycation end products on health
DOI:
https://doi.org/10.15584/ejcem.2018.4.10Keywords:
advanced glycation end products, AGEs, CML, diabetes, glycationAbstract
Introduction. Advanced glycation end products (AGEs) are compounds formed endogenously in the human body. Besides this source of AGEs, they also exist in food and can be generated during cooking. Enhanced endogenous generation and intake of dietary AGEs have physiological impact on human health and are associated with progression of many diseases, including diabetes and its complications.
Aim. The purpose of this review is to the present the current state of knowledge about the various negative effects of advanced glycation end products on human health.
Material and methods. This study is based on analysis of literature reporting the content of AGEs in food and high or low AGEs dietary interventions in human and animal subjects.
Results. Literature data present databases gathering description of AGEs determinations in various types of food.
Conclusion. Excessive consumption of AGEs-rich products, especially abundant in protein and fat or cooked for a long time at high temperature, may contribute to the deterioration of human health, including development of hypertension, insulin resistance, and diabetic complications.
Downloads
References
Sadowska-Bartosz I, Galiniak S, Bartosz G. Kinetics of glycoxidation of bovine serum albumin by methylglyoxal and glyoxal and its prevention by various compounds. Molecules. 2014;19:4880-4896.
Ahmed MU, Brinkmann Frye E, Degenhardt TP, Thorpe SR, Baynes JW. N-epsilon-(carboxyethyl)lysine, a product of the chemical modification of proteins by methylglyoxal, increases with age in human lens proteins. Biochem J. 1997;324 (Pt 2):565-570.
Kim CS, Park S, Kim J. The role of glycation in the pathogenesis of aging and its prevention through herbal products and physical exercise. J Exerc Nutrition Biochem. 2017;21(3):55-61.
Vlassara H, Uribarri J. Advanced glycation end products (AGE) and diabetes: cause, effect, or both? Curr Diab Rep. 2014;14(1):453.
Li J, Liu D, Sun L, Lu Y, Zhang Z. Advanced glycation end products and neurodegenerative diseases: mechanisms and perspective. J Neurol Sci. 2012;317(1-2):1-5.
Hegab Z, Gibbons S, Neyses L, Mamas MA. Role of advanced glycation end products in cardiovascular disease. World J Cardiol. 2012;4(4):90-102.
Rabbani N, Thornalley PJ. Advanced glycation end products in the pathogenesis of chronic kidney disease. Kidney Int. 2018;93(4):803-813.
Okura T, Ueta E, Nakamura R, et al. High serum advanced glycation end products are associated with decreased insulin secretion in patients with type 2 diabetes: A brief report. J Diabetes Res. 2017;2017:5139750.
Tan KC, Shiu SW, Wong Y, Tam X. Serum advanced glycation end products (AGEs) are associated with insulin resistance. Diabetes Metab Res Rev. 2011;27(5):488-492.
Ko SY, Ko HA, Shieh TM, et al. Advanced glycation end products influence oral cancer cell survival via Bcl-xl and Nrf-2 regulation in vitro. Oncol Lett. 2017;13(5):3328-3334.
Sharaf H, Matou-Nasri S, Wang Q, et al. Advanced glycation endproducts increase proliferation, migration and invasion of the breast cancer cell line MDA-MB-231. Biochim Biophys Acta. 2015;1852(3):429-441.
Szkudlarek A, Sułkowska A, Maciążek-Jurczyk M, Chudzik M, Równicka-Zubik J. Effects of non-enzymatic glycation in human serum albumin. Spectroscopic analysis. Spectrochim Acta A Mol Biomol Spectrosc. 2016;152:645-653.
Luevano-Contreras C, Chapman-Novakofski K. Dietary advanced glycation end products and aging. Nutrients. 2010;2(12):1247-1265.
Ames JM1. Determination of N epsilon-(carboxymethyl)lysine in foods and related systems. Ann N Y Acad Sci. 2008;1126:20-24.
Yuan X, Zhao J, Qu W, et al. Accumulation and effects of dietary advanced glycation end products on the gastrointestinal tract in rats. Int J Food Sci Technol. 2018;53:2273-2281.
Koschinsky T, He CJ, Mitsuhashi T, et al. Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci USA. 1997;94(12):6474-6479.
Semba RD, Nicklett EJ, Ferrucci L. Does accumulation of advanced glycation end products contribute to the aging phenotype? J Gerontol A Biol Sci Med Sci. 2010;65(9):963-975.
Takeuchi M, Takino J, Furuno S, et al. Assessment of the concentrations of various advanced glycation end-products in beverages and foods that are commonly consumed in Japan. PLoS One. 2015;10(3):e0118652.
Scheijen JLJM, Clevers E, Engelen L, et al. Analysis of advanced glycation endproducts in selected food items by ultra-performance liquid chromatography tandem mass spectrometry: Presentation of a dietary AGE database. Food Chem. 2016;190:1145-1150.
Uribarri J, Woodruff S, Goodman S, et al. Advanced glycation end products in foods and a practical guide to their reduction in the diet. J Am Diet Assoc. 2010;110(6):911-16.e12.
Chen G, Smith JS. Determination of advanced glycation endproducts in cooked meat products. Food Chem. 2015;168:190-195.
Hulla GLJ, Woodsideb JV, Amesc JM, Cuskelly GJ. Nε-(carboxymethyl)lysine content of foods commonly consumed in a Western style diet. Food Chem. 2012:131(1):170-174.
Mitra B, Lametsch R, Greco I, Ruiz-Carrascal J. Advanced glycation end products, protein crosslinks and post translational modifications in pork subjected to different heat treatments. Meat Sci. 2018;145:415-424.
Chao P, Hsu C, Yin M. Analysis of glycative products in sauces and sauce-treated foods. Food Chem. 2009;113(1):262-266.
Sadowska-Bartosz I, Bartosz G. Prevention of protein glycation by natural compounds. Molecules. 2015;20:3309-3334.
Uribarri J, Stirban A, Sander D, et al. Single oral challenge by advanced glycation end products acutely impairs endothelial function in diabetic and nondiabetic subjects. Diabetes Care. 2007;30:2579-2582.
Scheijen JLJM, Hanssen NMJ, van Greevenbroek MM, et al. Dietary intake of advanced glycation endproducts is associated with higher levels of advanced glycation endproducts in plasma and urine: The CODAM study. Clin Nutr. 2018;37(3):919-925.
Macías-Cervantes MH, Rodríguez-Soto JM, Uribarri J, Díaz-Cisneros FJ, Cai W, Garay-Sevilla ME. Effect of an advanced glycation end product-restricted diet and exercise on metabolic parameters in adult overweight men. Nutrition. 2015;31(3):446-451.
Semba RD, Gebauer SK, Baer DJ, et al. Dietary intake of advanced glycation end products did not affect endothelial function and inflammation in healthy adults in a randomized controlled trial. J Nutr. 2014;144(7):1037-1042.
Semba RD, Ang A, Talegawkar S, et al. Dietary intake associated with serum versus urinary carboxymethyl-lysine, a major advanced glycation end product, in adults: the Energetics Study. Eur J Clin Nutr. 2012;66(1):3-9.
Sebeková K, Krajcoviová-Kudlácková M, Schinzel R, Faist V, Klvanová J, Heidland A. Plasma levels of advanced glycation end products in healthy, long-term vegetarians and subjects on a western mixed diet. Eur J Nutr. 2001;40(6):275-281.
Sebeková K, Somoza V, Jarcusková M, Heidland A, Podracká L. Plasma advanced glycation end products are decreased in obese children compared with lean controls. Int J Pediatr Obes. 2009;4(2):112-118.
Mirmiran P, Yousefi R, Mottaghi A, Azizi F. Advanced glycation end products and risk of hypertension in Iranian adults: Tehran lipid and glucose study. J Res Med Sci. 2018;23:43.
Di Pino A, Currenti W, Urbano F, et al. High intake of dietary advanced glycation end-products is associated with increased arterial stiffness and inflammation in subjects with type 2 diabetes. Nutr Metab Cardiovasc Dis. 2017;27(11):978-984.
Mark AB, Poulsen MW, Andersen S, et al. Consumption of a diet low in advanced glycation end products for 4 weeks improves insulin sensitivity in overweight women. Diabetes Care. 2014;37(1):88-95.
Baye E, Kiriakova V, Uribarri J, Moran LJ, de Courten B. Consumption of diets with low advanced glycation end products improves cardiometabolic parameters: meta-analysis of randomised controlled trials. Sci Rep. 2017;7(1):2266.
Lv X, Lv GH, Dai GY, Sun HM, Xu HQ. Food-advanced glycation end products aggravate the diabetic vascular complications via modulating the AGEs/RAGE pathway. Chin J Nat Med. 2016;14(11):844-855.
Li RL, Zhao WW, Gao BY. Advanced glycation end products induce neural tube defects through elevating oxidative stress in mice. Neural Regen Res. 2018;13(8):1368-1374.
Skovgaard D, Svensson RB, Scheijen J, et al. An advanced glycation endproduct (AGE)-rich diet promotes accumulation of AGEs in Achilles tendon. Physiol Rep. 2017;5(6).pii:e13215.
Sowndhar Rajan B, Manivasagam S, Dhanusu S, et al. Diet with high content of advanced glycation end products induces systemic inflammation and weight gain in experimental mice: Protective role of curcumin and gallic acid. Food Chem Toxicol. 2018;114:237-245.
Patel R, Baker SS, Liu W, et al. Effect of dietary advanced glycation end products on mouse liver. PLoS One. 2012;7(4):e35143.
Zheng F, He C, Cai W, Hattori M, Steffes M, Vlassara H. Prevention of diabetic nephropathy in mice by a diet low in glycoxidation products. Diabetes Metab Res Rev. 2002;18(3):224-237.
Borg DJ, Yap FYT, Keshvari S, et al. Perinatal exposure to high dietary advanced glycation end products in transgenic NOD8.3 mice leads to pancreatic beta cell dysfunction. Islets. 2018;10(1):10-24.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2018 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
